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Background: Low serum cholesterol levels are related to an increased risk of depression and its serious
consequences. However, the effect of central cholesterol on depressive disorder and its potential regulatory
mechanism is poorly understood. Therefore, brain cholesterol in patients with depression may not only decrease
the risk for developing this disease but also increase the beneficial effects of treatment for depression.
Methods: In current study, rats were exposed to chronic mild stress (CMS) for consecutive 28 days, and the
depressive-like behavior was tested by sucrose preference test, immobility in the forced swim test, locomotor
activity in the open field test, decreased bodyweight and food intake. Additionally, the total cholesterol levels in the
medial prefrontal cortex (mPFC) and the hippocampus of rats were measured by gas chromatograph mass
spectrometer. Finally, 5-HT1A receptor antagonist WAY100635 was used to determine the potential role of serotonin
system in the interaction between central cholesterol and depression.
Results: CMS significantly reduced total cholesterol levels in the mPFC but not in the hippocampus and resulted in
depressive-like behavior. Chronic supplementation of cholesterol by food reversed the depressive-like behavior
induced by CMS. Furthermore, pre-injection of 5-HT1A receptor antagonist WAY100635 into the mPFC blocked the
treatment effects of cholesterol on the reversal of behavioral response.
Conclusion: This finding suggested that cholesterol in the mPFC may have an impact on the sensitivity of the
5-HT1A receptor in the development and treatment of depression. The treatment benefits of cholesterol could be
through modulation of the brain 5-HT1A receptor.
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Individuals with serious mental illness are at increased
risk for coronary artery disease. Acute coronary syn-
drome significantly decreases total cholesterol levels [1].
Aberrant lipid metabolism has also been observed in
coronary artery disease patients with or without de-
pression [2,3], as well as those with depression who
are otherwise medically healthy [4,5], suggesting that
lipid signaling plays a key role in the comorbidity.
Patients with major depressive disorder (MDD) may
have significant differences in cholesterol levels* Correspondence: yangs_ahqu@163.com
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suggests that low serum total cholesterol levels related
to an increased risk of depression and its serious conse-
quences [7]. Most recently, low serum cholesterol levels
have also been associated with suicidal behavior [8-11].
However, the effect of central cholesterol on depressive
disorder is poorly understood.
It has been proposed that brain synaptosomal membrane
cholesterol might determine the number of serotonin recep-
tors [8]. Low membrane cholesterol decreases the number of
serotonin receptors. Therefore, disturbed cholesterol levels
may be associated with serotonergic dysfunction. There are
ample evidences for a critical involvement of serotonergic re-
ceptors, particularly 5-HT1A, in the pathophysiology andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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HT1A agonists increase prefrontal dopamine release [14,15].
As a consequence, the 5-HT1A receptor serves as an import-
ant target in the development of therapeutic agents for
neuropsychiatric disorders such as anxiety and depression
[16]. Previous study has demonstrated the requirement of
membrane cholesterol in the organization, dynamics, and
function of the 5-HT1A receptor [17,18]. Additionally, it has
been shown that there is a significant reduction in the level
of specific ligand binding and G-protein coupling to 5-HT1A
receptors upon chronic cholesterol depletion, although the
membrane receptor level is not reduced at all [18]. There-
fore, we hypothesized that 5-HT1A receptors could be in-
volved in the induction of depression by chronic mild stress
through cholesterol reduction. Recent neuroimaging and
medial post-mortem studies showed altered activity of
discrete regions within the hippocampus and prefrontal cor-
tex (mPFC) and their atrophy are associated with depression
[19-21]. In addition, 5-HT1A heteroreceptors are abundantly
expressed post-synaptically in the PFC, amygdala, and hippo-
campus to mediate serotonin actions on fear, anxiety, stress,
and cognition, indicating a primary role of the 5-HT-PFC cir-
cuitry in effective treatment of depression [22-24].
Based on these findings, the present study examines
whether the changes of brain cholesterol levels are in-
volved in the depressive symptoms in chronic mild stress
procedure and the modulation of 5-HT system in the
prefrontal cortex. Furthermore, another aim of this study
is to investigate the possibility that the combined admin-
istration of 5-HT1A receptor antagonist and cholesterol
supplementation reverses the induction of depressive
symptoms by chronic mild stress.
Methods
Animals and diets
Male Sprague-Dawley rats that weighed 200-220 g upon
arrival were individually housed under a constant
temperature (23 ± 2°C) and a 12 h/12 h light/dark cycle
with free access to food and water before the initiation
of the experiment. The experimental diet for supplemen-
tary cholesterol was provided by the experimental ani-
mal centre of our hospital with 1 g/kg of cholesterol and
sufficient amounts of protein, minerals and vitamins for
healthy maintenance. All of the animal procedures were
performed in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Ani-
mals, and the procedures were approved by the Local
Animal Use Committee. All of the behavioral tests and
drug administrations were performed in the dark phase.
Drugs
The selective 5-HT1A receptors antagonist WAY100635
maleate (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in saline (0.9% NaCl). The solutions were preparedimmediately before the stress and protected from the
light during the experimental sessions. The dose of
WAY100635 used for microinjection was selected as
40 nmol/μl based on previous reports [25].
Intracerebral cannula implantation and intracranial
injections
The rats were anesthetized with sodium pentobarbital (60
mg/kg, i.p.), and guide cannulae (23-gauge, Plastics One, Ro-
anoke, VA, USA) were placed at a 23° angle toward the mid-
line and implanted bilaterally 1 mm above the medial
prefrontal cortex with the following stereotaxic coordinates:
anterior/posterior (A/P), -3.2 mm; medial/lateral (M/L), ±
2.5 mm; dorsal/ventral (D/V), -3.3 mm [26,27]. Vehicle, or
WAY100635 was intracranially microinjected using 10 μl
Hamilton syringes (Hamilton, Reno, NV, USA) that were
connected via polyethylene-50 tubing to 30-gauge injectors
(Plastics One). A total volume of 0.5 μl was infused into each
side over 1 min, and the injection syringe was left in place
for an additional 1 min to allow for diffusion. At the end of
the experiments, the rats were anesthetized with sodium
pentobarbital (100 mg/kg, i.p.) and transcardially perfused.
Cannula placements were assessed using Nissl staining with
a thickness of 30 μm under light microscopy. Subjects with
misplaced cannulae and pathological damage were excluded
from the statistical analysis.
Behavioral tests
Chronic mild stress protocol
The chronic mild stress protocol was adapted from previ-
ous study [28]. Briefly, rats were subjected to different
mild stressors for 28 days: Day 1 (cold immobilization for
1 h at 4°C, tilted cages 45° for 24 h), Day 2 (immobilization
for 1 h, crowding for 24 h), Day 3 (forced cold swim for 5
min, soiled bedding for 24 h), Day 4 (immobilization for
1 h, vibration for 1 h), Day 5 (tilted cages 45° for 24 h, cold
immobilization for 1 h at 4°C), Day 6 (forced cold swim
for 5 min at 4°C, crowding for 24 h), and Day 7 (vibration
for 1 h, soiled bedding for 24 h). This schedule was re-
peated three more times (Table 1). Control rats were han-
dled daily without any stress in the housing room.
Sucrose preference test
The measurement of sucrose preference was performed
as previously described [29]. The rats were trained to
adapt to a 1% sucrose solution (w/v) for 48 h at the be-
ginning of the experiment, during which two bottles of
1% sucrose solution were placed in each cage. After
adaptation, rats were deprived of water and food for
24 h, followed by the sucrose preference test, in which
the rats were housed in individual cages for 4 h and had
free access to two bottles that contained 1% sucrose or
tap water. The bottles were counterbalanced across the
left and right sides of the cages throughout the experiment.
Table 1 The protocol and stress procedures for chronic
mild stress
Date Stressor
Monday Cold immobilization for 1 h at 4°C, tilted cages 45° for 24 h
Tuesday Immobilization for 1 h, crowding for 24 h
Wednesday Forced cold swim for 5 min, soiled bedding for 24 h
Thursday Immobilization for 1 h, vibration for 1 h
Friday Tilted cages 45° for 24 h, cold immobilization for 1 h at 4°C
Saturday Forced cold swim for 5 min at 4°C, crowding for 24 h
Sunday Vibration for 1 h, soiled bedding for 24 h
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the test. At the end of 4 h, sucrose and water consumption
(in milliliters) was measured, and sucrose preference (%)
was calculated as the ratio of sucrose consumption to su-
crose plus water consumption.
Forced swim test
The rats were placed in a 25 cm diameter × 65 cm
height plastic cylinder that was filled to a depth of 30
cm with 23-25°C water for 15 min. The rats were tested
24 h later. Immobility was defined as the minimum
movement required to passively keep the animal’s head
above the water without other motions. The results are
expressed as the time (in seconds) that the animals spent
immobile during the 5 min test [30].
Open field test
The open field test was used to measure locomotor ac-
tivity as previously described [31]. Briefly, the apparatus
consisted of a 75 cm × 75 cm × 40 cm square arena di-
vided into 25 equal squares (15 cm × 15 cm) on the
floor of the arena. A single rat was placed in the center
of the apparatus, and the number of crossings (i.e., en-
tries into adjacent squares) was counted for 5 min.
Measurement of cholesterol levels
Rats were killed by decapitation after behavioral tests.
Their brains were quickly removed, dissected on ice and
collected for subsequent cholesterol analysis. Prior to ana-
lysis, the brain samples were spun in a speed vacuum dryer
(12 mbar; Savant AES 1000) for 24 h in order to express
the individual sterol concentrations relative to the dry
weight. The sterols were extracted from the dried tissue by
placing in a 1.5 ml mixture of chloroform/methanol (at a
2:1 ratio) for 24 h at 4°C. Sterol levels were determined by
a gas chromatograph mass spectrometer as described pre-
viously [32,33]. The blood samples were kept at room
temperature for 1 h and then centrifuged at 3000 rpm for
10 min. The serum supernatant fraction was stored in an-
other tube for the subsequent cholesterol assays.Tissue sample preparation
The rats were decapitated, and the brains were extracted
based on our previous study [34]. Subsequently, bilateral
tissue punches of the prefrontal cortex and hippocampus
(16 gauge) were obtained from approximately 1 mm
thick coronal sections cut in a Reichert-Jung 2800 Frigo-
cut E cryostat at -20°C. The rostral faces of the coronal
sections were approximately 3.2 mm for mPFC and -3.8
mm for hippocampus from bregma.
Intracerebral cannula implantation and intracranial
injections
The rats were anesthetized with sodium pentobarbital (60
mg/kg, i.p.), and guide cannulae (23-gauge, Plastics One,
Roanoke, VA, USA) were placed at a 23° angle toward the
midline and implanted bilaterally 1 mm above the medial
prefrontal cortex with the following stereotaxic coordinates:
anterior/posterior (A/P), -3.2 mm; medial/lateral (M/L), ±
2.5 mm; dorsal/ventral (D/V), -3.3 mm [26,27]. Vehicle or
WAY100635 (40 nmol/μl) was intracranially microinjected
using 10 μl Hamilton syringes (Hamilton, Reno, NV, USA)
that were connected via polyethylene-50 tubing to 30-
gauge injectors (Plastics One). A total volume of 0.5 μl was
infused into each side over 1 min, and the injection syringe
was left in place for an additional 1 min to allow for diffu-
sion. At the end of the experiments, the rats were anesthe-
tized with sodium pentobarbital (100 mg/kg, i.p.) and
transcardially perfused. Cannula placements were assessed
using Nissl staining with a thickness of 30 μm under light
microscopy. Subjects with misplaced cannulae were ex-
cluded from the statistical analysis.
Experimental design
Experiment 1: effects of chronic mild stress on the
cholesterol levels in the brain
In this section, we used two groups of rats (n = 8 per
group) to observe the possible impact of chronic mild
stress on the central levels of cholesterol. One group of rats
was subjected to chronic mild stress procedure for con-
secutive 28 days, while the other group rats were handled
normally without any stress during the period. One day
after the last stressor on day 29, rats were weighed, and the
sucrose preference test, open field test, forced swim test
and food intake in 1 h were measured consequently. After
the behavioral tests, rats were killed by decapitation, and
brain tissues of medial prefrontal cortex (mPFC) and
hippocampus were collected for further cholesterol assay.
Experiment 2: effects of cholesterol supplementation on the
depressive-like behavior
The purpose of this experiment was to investigate
whether chronic cholesterol supplementation by daily di-
ets reverses depressive-like behavior induced by chronic
mild stress. Four groups of rats (n = 8 per group) were
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terol) factorial design to test the effect of cholesterol
supplementation on the depressive-like behavior. Rats
were subjected to CMS or control without any stress for
28 days and received vehicle or cholesterol on the begin-
ning of the stress period. On day 29, the bodyweight was
measured, the sucrose preference test, open field test,
forced swim test and food intake in 1 h were performed
to determine the possible treatment effects of chronic
supplementation of cholesterol.
Experiment 3: role of chronic cholesterol treatment on the
cholesterol content in serum and brain
We further aimed to explore whether cholesterol supple-
mentation alters cholesterol content differentially in
medial prefrontal cortex and hippocampus. Four groups
of rats (n = 8 per group) were used in a 2 (control and
CMS) × 2 (vehicle and cholesterol) factorial design to
test the effect of supplementation on the cholesterol
level. Rats were subjected to CMS or control for 28 days
and received vehicle or cholesterol on the initiation of
the stress or control period. On day 29, rats were killed
by decapitation without behavioral tests, subsequently
blood and brain tissues of mPFC and hippocampus were
collected for further cholesterol assay.
Experiment 4: role of 5-HT1A receptor on the behavioral re-
sponses of cholesterol
To determine whether 5-HT system is involved in the
treatment effects of cholesterol, eight groups of rats (n = 8)
were used for either control or CMS, either vehicle or chol-
esterol, and either vehicle or WAY100635, respectively.
Rats were micro-injected with 5-HT1A receptor antagonist
WAY100635 (40 nmol/μl per side) or vehicle 1 h before
daily cholesterol provision during the 28-day chronic mild
stress process. On day 29, the bodyweight was measured,
the sucrose preference test, open field test, forced swim
test and food intake in 1 h were performed to determine
the regulatory role of 5-HT1A receptor on the behavioral
responses of cholesterol.
Data analysis
The data are expressed as mean ± SEM and were ana-
lyzed using one- or two-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test (for details,
see Results section). In the two-way ANOVA tests, two
factors are involved: 1. CMS and non-CMS groups, 2.
diet with and without cholesterol treatment. Values of
P < 0.05 were considered statistically significant.
Results
Chronic mild stress induced depressive-like behavior in rats
Rats subjected to chronic mild stress for 28 days, one of
the most valid models of depression, showed anhedoniastate as demonstrated by the decrease in sucrose preference
(P < 0.01, Figure 1a) with on effects on the total water in-
take (Figure 1b) compared with rats in control group. In
the forced swim test, the immobility was significantly in-
creased by chronic mild stress procedure (P < 0.01,
Figure 1c), suggesting a behavioral despair induced by
chronic stress. Additionally, chronic mild stress re-
duced the locomotor activity of rats in the open field
test (P < 0.01, Figure 1d). Furthermore, we also found
that chronic mild stress decreased both the body-
weight (P < 0.01, Figure 1e) and the food intake (P <
0.01, Figure 1f ) compared with control rats. These be-
havioral results suggest that chronic mild stress in-
duced depressive-like behavior in rats.
Chronic mild stress decreased cholesterol levels
Cholesterol determination revealed that rats in chronic
mild stress exposure produced lower cholesterol levels
in the medial prefrontal cortex (P < 0.01, Figure 2a) but
not the hippocampus (P > 0.05, Figure 2b) compared to
control rats. These findings suggested that the decreased
cholesterol levels in the medial prefrontal cortex might
be associated with the induction of depressive-like be-
havior in the chronic mild stress procedure.
Chronic low dose of cholesterol supplementation
prevented depressive-like behavior induced by chronic
mild stress
We further determine whether pre-treatment with choles-
terol before daily stress could prevent the development of
depressive-like behavior induced by chronic mild stress. A
different set of rats was used in this section (Figure 3a). The
results showed that cholesterol added in food for 28 days sig-
nificantly reversed the depressive-like behavior induced by
chronic mild stress as indicated by increased sucrose prefer-
ence (P < 0.05, Figure 3b, c), decreased immobility (P < 0.01,
Figure 3d) in the forced swim test, increased crossings in the
open field test (P < 0.01, Figure 3e) and increased body-
weight (P < 0.05, Figure 3f) and food intake (P < 0.01,
Figure 3g). The analysis of the sucrose preference data re-
vealed a significant effect of CMS (F1,28 = 66.20, P < 0.001)
and cholesterol (F1,28 = 6.68, P < 0.05) and a significant
CMS × cholesterol interaction (F1,28 = 5.71, P < 0.05) for
sucrose preference. The analysis of immobility in forced
swim test showed a significant effect of CMS (F1,28 =
31.09, P < 0.001) and cholesterol (F1,28 = 5.69, P <
0.05) and a significant CMS × cholesterol interaction
(F1,28 = 5.30, P < 0.05). Additionally, the data analysis
of crossings in the open field test showed a significant
effect of CMS (F1,28 = 15.71, P < 0.001) and choles-
terol (F1,28 = 5.46, P < 0.05) and a significant CMS ×
cholesterol interaction (F1,28 = 5.90, P < 0.05). Further-
more, the data analysis of bodyweight changes re-
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Figure 1 Chronic mild stress induced depressive-like behavior in rats. The behavioral tests were conducted after 28-day chronic mild stress.
(a) sucrose preference, (b) total water intake, (c) immobility in the forced swim test, (d) locomotor activity in the open field test, (e) bodyweight,
(f) food intake. Data are expressed as mean ± SEM (n = 8 per group). Differences between control and CMS were assessed using Tukey’s post hoc
test. **P < 0.01 compared with control rats. CMS, chronic mild stress.




















































Figure 2 Chronic mild stress decreased cholesterol levels. The levels of cholesterol were significantly decreased by CMS in the medial
prefrontal cortex (a) but not in the hippocampus (b). Data are expressed as mean ± SEM (n = 8 per group). Differences between control and
CMS were assessed using Tukey’s post hoc test. **P < 0.01 compared with control rats. CMS, chronic mild stress.
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Figure 3 Chronic cholesterol treatment prevented depressive-like behavior induced by chronic mild stress. (a) Schemes of experimental
schedules, (b) sucrose preference, (c) total water intake, (d) immobility in the forced swim test, (e) locomotor activity in the open field test,
(f) bodyweight, (g) food intake. Data are expressed as mean ± SEM (n = 8 per group). Differences between control and CMS were assessed using
two-way ANOVA followed Tukey’s post hoc test. **P < 0.01 compared with control rats. #P < 0.05, ##P < 0.01 compared with cholesterol-treated
chronic mild stress rats.
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significant CMS × cholesterol interaction (F1,28 = 7.05,
P < 0.05). Finally, the food intake data analysis showed
a significant effect of CMS (F1,28 = 18.06, P < 0.001)
and cholesterol (F1,28 = 6.41, P < 0.05) and a significant
CMS × cholesterol interaction (F1,28 = 6.57, P < 0.05).These results suggested that cholesterol homeostasis in
the central nervous system plays a key role in the de-
pression, especially the stress-related mood disorder.
Critical modulation of cholesterol level might be benefit
for the treatment and recovery of depressed patients in
the clinic.
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content in medial prefrontal cortex but not hippocampus
It is interesting to find that there is a reduction in
cholesterol content in medial prefrontal cortex but not
in hippocampus upon subjecting rats to chronic mild
stress. Therefore, it is important to clarify whether
supplementation alters cholesterol content differen-
tially in these two regions. The results showed that
chronic cholesterol treatment for 28 days increased choles-
terol content in medial prefrontal cortex (Figure 4a,b) of
rats in chronic mild stress. The two-way ANOVA analysis
showed a significant effect of CMS (F1,28 = 25.70,
P < 0.001) and cholesterol (F1,28 = 5.40, P < 0.05) and a sig-





























































Figure 4 Chronic cholesterol treatment increased the cholesterol con
(a) Schemes and timeline of experimental schedules, Total cholesterol con
Data are expressed as mean ± SEM (n = 8 per group). Differences betwee
Tukey’s post hoc test. ***P < 0.001 compared with control rats. ##P < 0.01 cP < 0.05) for cholesterol content in the medial prefrontal
cortex. However, chronic cholesterol treatment for 28 days
did not change the cholesterol content in hippocampus
(Figure 4c). In addition, the serum cholesterol content was
not altered by cholesterol supplementation (Figure 4d).
These findings suggested that increase of cholesterol in
medial prefrontal cortex, but not hippocampus, by oral
cholesterol supplementation is related to the prevention of
depressive-like behavior.
Antagonism of 5-HT1A receptor blocked the behavioral
responses of cholesterol in CMS procedure
To further examine the regulatory role of 5-HT system
in the relationship between cholesterol dysfunction andntal schedules
28 29





























tent in medial prefrontal cortex but not hippocampus.
tent in (b) medial prefrontal cortex, (c) hippocampus and (d) serum.
n control and CMS were assessed using two-way ANOVA followed


















































































































Control CMS Control CMS
Control CMS Control CMS


















a    Schemes of experimental schedules
1 28 29(days)
Chronic mild stress
vehicle or cholesterol 
Behavioral tests 
vehicle or WAY 
Figure 5 Antagonism of 5-HT1A receptor blocked the behavioral responses of cholesterol in chronic mild stress procedure. (a) Schemes
of experimental schedules, (b) sucrose preference, (c) total water intake, (d) immobility in the forced swim test, (e) locomotor activity in the open
field test, (f) bodyweight, (g) food intake. Data are expressed as mean ± SEM (n = 8 per group). Differences between control and CMS were
assessed using two-way ANOVA followed Tukey’s post hoc test. **P < 0.01, ***P < 0.001 compared with control rats. ##P < 0.01 compared with
cholesterol-treated chronic mild stress rats.
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(n = 8 per group) either to chronic mild stress or control
administration, and cholesterol or 5-HT1A receptor an-
tagonist WAY100635 was microinjected into the medial
prefrontal cortex during 28 days (Figure 5a). One day
after the last stressor, we measured the depressive-like
behavior of these rats. We found that infusion of
WAY100635 significantly reversed the behavioral re-
sponse of supplementation of cholesterol in the chronic
mild stress procedure. Chronic cholesterol provision in-
creased the sucrose preference in stress-treated rats (F1,28 =
20.81, P < 0.001, Figure 5b, c), however, WAY100635 pre-
vented this reversal effects of cholesterol (F1,28 = 6.51, P <
0.05). Moreover, the reduction of immobility in the forcedswim test (F1,28 = 11.69, P < 0.01, Figure 5d) and crossings in
the open field test (F1,28 = 5.19, P < 0.05, Figure 5e) was also
blocked by WAY100635. Similarly, the increased bodyweight
(F1,28 = 10.73, P < 0.01, Figure 5f) and food intake (F1,28 =
5.38, P < 0.05, Figure 5g) was both reversed by WAY100635
microinjection. This finding suggested that cholesterol may
have an impact on the sensitivity of the 5-HT receptors in
the interactions between stress and depression.
Discussion
In the current investigation, we found that chronic mild
stress induced depressive-like behavior in rats associ-
ated with decreased cholesterol levels in the medial pre-
frontal cortex. However, pre-treatment with cholesterol
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depressive-like behavior induced by chronic mild stress.
Finally, intra-mPFC infusion of 5-HT1A receptor antag-
onist WAY100635 significantly reversed the behavioral
response of supplementation of cholesterol in the chronic
mild stress procedure. This data suggested that regulation
of 5-HT1A receptor participated in the development of
depression through control of central cholesterol in rats.
In patients with coronary artery disease, the prevalence of
several diseases has been increased, such as type 2 dia-
betes mellitus [35,36] and symptoms of depression [37],
leading to increased risk for further cardiac events after
acute coronary syndrome. Moreover, about 17%–27% of
patients with coronary artery disease have major depres-
sion, and a significantly larger percentage have subsyn-
dromal symptoms of depression [38]. Depression has
been linked to higher health care costs and to worse
outcomes in patients with coronary artery disease
[39,40]. Selective serotonin reuptake inhibitors (SSRIs)
are the first-line antidepressants among patients with
coronary artery disease with a lower risk of death/recur-
rent myocardial infarction [41].
Since low and higher level of serum total cholesterol is
a stable feature in some persons with recurrent major
depression, the level of total cholesterol in blood sam-
ples in patients with major depression has been widely
used to estimate the risk of suicidal behavior in the pres-
ence of depressive disorder [42]. Consistent with previ-
ous findings that serum cholesterol was decreased in
depressed patients, our results showed that the choles-
terol levels in the medial prefrontal cortex were signifi-
cantly decreased in rats that were exposed to chronic
mild stress for a long period. According to this data, we
therefore proposed that the reduced central levels of
cholesterol might be related with the onset of
depressive-like behavior in rats. However, not all studies
suggested a relationship between lower cholesterol and
depression. There are some evidences showed that the
elevated cholesterol levels were seen in depressed pa-
tients [43]. Furthermore, there are strong evidences indi-
cated that serum cholesterol level was increased in
patients with coronary artery diseases. However, we fo-
cused on the changes of cholesterol level in the central
nervous system in our current study. Our data showed
cholesterol was decreased in the medial prefrontal cor-
tex, but not in the hippocampus, of the brain in rats ex-
posed to chronic mild stress, which suggested that the
alteration of cholesterol in specific brain region might
play a different role in the regulation of mood by specific
downstream signal pathway. There are many differences
between medial prefrontal cortex and hippocampus be-
yond the number of 5-HT1A receptor. It has been evi-
denced that chronic mild stress significantly decreased
PSD95, a key synaptic protein that co-localizes withNMDA receptors at synapses, inhibited mTOR function
by decreasing phosphorylated p70s6k and rps6 in the
medial prefrontal cortex but not hippocampus [44]. In-
duction of PSD-95 is consistent with increased synapse
formation and function. mTOR signaling pathways have
been implicated in the increase in synaptic plasticity and
new spine formation. Therefore, we raised the possibility
that these post-synaptic signal pathways in the medial
prefrontal cortex might play a central role in depression
symptoms after cholesterol treatment.
The relationship between cholesterol levels, depressive
behavior and serotonergic function could be explained
that the changed levels of cholesterol are directly re-
sponsible for alterations in serotonergic function in de-
pression. Cholesterol is an important membrane lipid
and is essential in regulating the properties of cell mem-
branes in mammalian cells organization, dynamics, func-
tion, and sorting [45,46].
Several studies showed that chronic administration of
stress hormone, such as glucocorticoid corticosterone and
adrenocorticotropic hormone, increases muscle tissues and
plasma cholesterol in animals [47,48]. However, there is no
direct evidence revealed the effects of stress on the levels
of cholesterol in the central nervous system. Additionally,
other abnormalities related to lipid homeostasis described
in depressed patients include an increase in the activity of
enzymes involved in lipid oxidation and peroxidation [49],
lower vitamin E concentrations [50], and lower serum
high-density lipoprotein-cholesterol (HDL-C) levels [51].
Previous study showed that simvastatin, a cholesterol-
lowering agent, increased the expression of brain-derived
neurotrophin factor (BDNF) and vascular endothelial
growth factor (VEGF) in the dentate gyrus (DG) of the
hippocampus in rats after traumatic brain injury, suggest-
ing an improvement of cognitive function [52]. Further-
more, pravastatin administration promotes neurological
recovery in ischemic stroke animals and induces neurogen-
esis in the DG and subventricular zone (SVZ), and in-
creases the number of migration cells in the striatum [53].
Cholesterol exists in plasma membrane has been evidence
to play an important role in neuronal differentiation, syn-
aptogenesis and axonal guidance [54]. These findings
raised the possibility that regulation of cholesterol might
play a role on neuroprotection and neurogenesis, which is
associated with the stress and depressive disorder. More-
over, serotonin plays a direct and acute regulatory role in
activity-dependent hippocampal neurogenesis [55]. There-
fore, it could be possible that understanding of cholesterol
on the regulation of neurogenesis might offer preventive
therapeutic opportunities in depression. Additionally, the
changes of cholesterol in serum affect neurotransmission
in the central nervous system [10]. The specific neuro-
transmitter by which cholesterol regulated in the patho-
physiology of depression needs further clarification.
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tor in the prefrontal cortex in rats [56]. Additionally, early-
life stress increased 5-HT1A receptor mRNA expression in
the amygdala, and reduced its expression in the dorsal raphé
nucleus [57]. These findings suggest that stress induces per-
sistent changes in 5-HT1A receptor and expression in major
brain regions involved in the development of stress-related
psychiatric disorders. In our current study, we found that
intra-mPFC infusion of 5-HT1A receptor antagonist
WAY100635 significantly reversed the behavioral response
of supplementation of cholesterol in the chronic mild stress
procedure. Previous evidence also showed that membrane
cholesterol plays a key role in the stability of the human
serotonin (1A) receptor [58]. It can be presumed that chol-
esterol binds 5-HT1A receptors [59] and therefore induces
translocation to increase serotonin release to counteract de-
pression. Therefore, further studies are required to clarify
the cellular mechanisms through which this relationship be-
tween cholesterol and depression works.
Conclusion
In summary, chronic supplementation of cholesterol by
food reversed the depressive-like behavior induced by
chronic mild stress in rats. Furthermore, pre-injection
with 5-HT1A receptor antagonist WAY100635 into the
medial prefrontal cortex blocked the treatment effects of
cholesterol on the reversal of behavioral response. The
present finding revealed that cholesterol may have an
impact on the sensitivity of the 5-HT receptors in the
interactions between stress and depression. The treat-
ment benefits of cholesterol could be acting through
modulation of the brain serotonin system especially in
the medial prefrontal cortex.
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